• Home
  • Caregen Co.,Ltd.

Caregen Co.,Ltd.

About Caregen Co.,Ltd.

Caregen, a global leader in peptide R&D, is a South Korean biotechnology company that has commercialized theexpandability of its patented peptides into innovative products since 2001. With over 1,500 functional peptidesdeveloped over 24 years, Caregen has redefined possibilities in cosmeceuticals, Class III medical devices, nutraceuticals,and pharmaceuticals.

Caregen aims to enhance life and health by delivering total healthcare solutions through the development, production,and global supply of advanced functional peptides. 

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • KR
  • 2016
    On CPHI since
  • 100 - 249
    Employees
Company types
Manufacturer/Innovator
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Korea 2025

COEX, Seoul, Korea
26 Aug 2025 - 28 Aug 2025
View Exhibitor Profile

CPHI Frankfurt 2025

Messe Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Products from Caregen Co.,Ltd. (5)

  • ProGsterol

    Product ProGsterol

    Clinically Validated Peptide-Based Food Supplement for Metabolic Health

    ProGsterol is an innovative oral metabolic peptide solution developed by Caregen to target the multifactorial pathology of major metabolic diseases, including type 2 diabetes, non-alcoholic steatohepatitis (NASH), and obesit...
  • MyoKi

    Product MyoKi

    MyoKi: Muscle Health Redefined in the GLP-1 Era

    As GLP-1 agonists gain global popularity for weight loss and metabolic control, concerns over unintended muscle loss—particularly in older adults and non-obese individuals—are growing. MyoKi offers a novel, peptide-based solution that counteracts t...
  • Korglutide

    Product Korglutide

    Korglutide is an orally administered GLP-1 peptide developed by Caregen as a next-generation solution for weight loss and metabolic improvement. Unlike injectable GLP-1 receptor agonists (e.g., semaglutide, liraglutide), Korglutide is designed as a nutraceutical that offers once-daily oral administration, ...
  • CG-P5

    Product CG-P5

    VEGFR2-Inhibiting Peptide Eye Drop for Wet Age-Related Macular Degeneration (wAMD)

    CG-P5 is the world’s first VEGFR2-inhibiting peptide formulated as a topical eye drop for the treatment of wet agerelated macular degeneration (wAMD). Unlike intravitreal anti-VEGF injections (e.g., Eylea, Lucenti...
  • CG-T1

    Product CG-T1

    Next-Generation Peptide-Based Therapy for Dry Eye Disease (DED)

    CG-T1 is a novel topical peptide therapeutic candidate under preclinical development for the treatment of dry eye disease (DED). Unlike conventional cyclosporine-based eye drops, CG-T1 is designed to offer rapid onset of action, a m...

Caregen Co.,Ltd. Resources (1)